share_log

Y-Mabs Therapeutics Said It Is Internally Realigning Operations With The Establishment Of Two Business Units: Radiopharmaceuticals And Danyelza And Announced 2025 Priorities

Benzinga ·  Jan 10 20:08
  • Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA
  • Preliminary Part A data from GD2-SADA Phase 1 trial demonstrates tolerability and validity of SADA PRIT platform pre-targeting approach; Company expects to present Part A data in the second quarter of 2025
  • Company reports preliminary estimated unaudited Total Net Revenue of approximately $88 million for the year ended December 31, 2024, within Full Year 2024 top line guidance range
  • Company reports preliminary estimated unaudited cash, cash equivalents and marketable securities of approximately $67 million as of December 31, 2024, anticipated to support operations into 2027
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment